<?xml version="1.0" encoding="ISO-8859-1"?>







<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<atom:link href="http://www.theheart.org/rssfeed.do" rel="self" type="application/rss+xml" />
<title>theHeart.org - Meeting coverage</title>
<link>http://www.theheart.org/condition/meeting-coverage.do</link>
<description></description>
<image>
 <url>http://www.theheart.org/documents/sitestructure/resources/images/maintho_logo_rss.png</url>
 <title>theHeart.org- Meeting coverage</title>
 <link>http://www.theheart.org/condition/meeting-coverage.do</link>
</image>



    <item>
    <link>http://www.theheart.org/article/1027255.do</link>
    <title>Stroke incidence related to PCI steady over 15 years </title>
    <description>
    <![CDATA[ Mayo Clinic researchers report that their stroke rate related to PCI has stayed steady for the last 15 years, something they interpret as good news, given that substantially older, sicker patients with more complex anatomy are now undergoing PCI.  ]]>
    </description>
    <pubDate>
    Fri, 20 Nov 2009 13:00:13 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1027255.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026921.do</link>
    <title>ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment </title>
    <description>
    <![CDATA[ New 10-year mortality and morbidity data confirm the original trial conclusions, they say, that while amlodipine and lisinopril are not superior to chlorthalidone on any outcome, chlorthalidone is superior to these agents on one or more secondary end points. Full agreement with this conclusion in the community, though, is still hard to come by.  ]]>
    </description>
    <pubDate>
    Thu, 19 Nov 2009 14:00:01 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026921.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026791.do</link>
    <title>Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI </title>
    <description>
    <![CDATA[ A dose-finding study saw what were characterized as low bleeding rates associated with triple-drug antithrombotic therapy that included the oral anticoagulant dabigatran in patients with a recent ACS event and other cardiovascular risk factors.   ]]>
    </description>
    <pubDate>
    Thu, 19 Nov 2009 11:00:11 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026791.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026701.do</link>
    <title>EFFECT: Public reporting of hospital performance improves quality of care? </title>
    <description>
    <![CDATA[ Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes. ]]>
    </description>
    <pubDate>
    Thu, 19 Nov 2009 10:00:55 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026701.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024841.do</link>
    <title>Kenneth Baughman killed while jogging at AHA</title>
    <description>
    <![CDATA[ <b><i>UPDDATED</i></b> //<i> </i>Dr Kenneth Baughman, a cardiologist at Brigham and Women's Hospital, died Monday morning in Orlando, FL, when he was struck by a car while out for a morning run. ]]>
    </description>
    <pubDate>
    Thu, 19 Nov 2009 08:30:46 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024841.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026477.do</link>
    <title>BARI 2D cost-effectiveness analysis favors medication over PCI for less severe CVD in diabetic patients</title>
    <description>
    <![CDATA[ New data from the BARI 2D trial comparing medical therapy vs revascularization in diabetics shows higher up-front costs of revascularization are only partially offset by long-term savings. ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 15:45:07 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026477.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026431.do</link>
    <title>Ticagrelor effects unraveled in new phase 2 trials </title>
    <description>
    <![CDATA[ New and unique phase 2 data add to the growing body of evidence explaining the pharmacologic effects of the new antiplatelet agent ticagrelor. ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 15:00:52 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026431.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1026349.do</link>
    <title>CT-STAT: CT angiography rules out CAD faster and cheaper than standard care</title>
    <description>
    <![CDATA[ The use of coronary CT angiography in the emergency room can successfully triage at-risk chest-pain patients and can do so faster and less expensively than standard diagnostic testing<b>.</b> ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 13:45:38 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1026349.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1025731.do</link>
    <title>Baseline function data from STICH no help in pinpointing patients who benefit from SVR</title>
    <description>
    <![CDATA[ Measures of left ventricular dysfunction or wall motion identified by different imaging modalities at baseline offer no clues as to whether a subset of patients treated with surgical ventricular reconstruction might benefit from the procedure.  ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 10:45:20 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1025731.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1025547.do</link>
    <title>ACC/AHA focused update of guidelines for STEMI, PCI </title>
    <description>
    <![CDATA[ The latest evidence for the treatment of STEMI and PCI has been incorporated into a fast-track update of US guidelines. But questions remain about the quality of some of the evidence informing the guidelines and about the composition of the writing committees.  ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 09:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1025547.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1025583.do</link>
    <title>JCHF: Are low doses of carvedilol effective in heart failure? </title>
    <description>
    <![CDATA[ Doses of carvedilol as low as 2.5 mg daily may be effective in Japanese patients with heart failure, according to this study. But experts said the trial was far too small to draw any meaningful conclusions.  ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 09:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1025583.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1025233.do</link>
    <title>Niacin not beneficial in patients at goal with statins: NIA Plaque</title>
    <description>
    <![CDATA[ The addition of niacin to statin therapy in secondary-prevention patients resulted in a significant improvement in lipids but failed to significantly alter atherosclerotic disease progression as measured by MRI. Researchers say it's a win for treating patients to target and suggest this trumps raising HDL. ]]>
    </description>
    <pubDate>
    Wed, 18 Nov 2009 09:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1025233.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024935.do</link>
    <title>RE-LY: Post hoc analysis confirms benefit of dabigatran relative to warfarin at all INR levels</title>
    <description>
    <![CDATA[ A new analysis confirms that regardless of INR control achieved across participating centers, dabigatran remained noninferior at the lower dose and superior at the higher dose to warfarin for prevention of stroke and systemic embolism. ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 16:30:06 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024935.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1022557.do</link>
    <title>Statins do not eliminate risk of low HDL-cholesterol levels</title>
    <description>
    <![CDATA[ Researchers say a new study shows that statins don't alter the risks associated with low HDL-cholesterol levels and that raising HDL cholesterol 10 mg/dL could prevent an additional eight MIs per 1000 patient-years. ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 14:45:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1022557.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024651.do</link>
    <title>POPE: No benefit of diclofenac on pericardial effusion </title>
    <description>
    <![CDATA[ Mean pericardial effusion grade postcardiac surgery was not reduced with 14 days of treatment with the NSAID. ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 10:00:33 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024651.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024575.do</link>
    <title>CASCADE: No significant benefit of clopidogrel in reducing graft disease after CABG </title>
    <description>
    <![CDATA[ Dual antiplatelet therapy did not significantly reduce vein graft intimal hyperplasia compared with aspirin alone over 12 months.  ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 09:00:24 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024575.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024539.do</link>
    <title>HEAAL: High-dose trumps low-dose ARB for heart failure in the ACE-inhibitor intolerant  </title>
    <description>
    <![CDATA[ <b><i>UPDATED WITH COMMENTARY </i></b>// The randomized trial, which compared losartan dosages of 150 mg/day and 50 mg/day, "makes a strong case for the value of incremental inhibition of the renin-angiotensin system," its authors say.   ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 08:15:58 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024539.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024429.do</link>
    <title>FAIR-HF: Symptom improvement, functional gains follow correction of iron deficiency in heart failure</title>
    <description>
    <![CDATA[ <b><i>UPDATED WITH COMMENTARY</i></b> // The randomized, placebo-controlled study's intriguing wrinkle: the benefits after 24 weeks of treatment with an injectable form of iron were independent of whether the patients were anemic.   ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 08:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024429.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024467.do</link>
    <title>HeartMate II continuous-flow VAD sets new benchmark in destination-therapy trial</title>
    <description>
    <![CDATA[ <b><i>UPDATED WITH COMMENTARY</i></b> // Thoratec's HeartMate II continuous-flow VAD keeps about half of patients alive and stroke- or reintervention-free after two years in pivotal destination therapy trial. ]]>
    </description>
    <pubDate>
    Tue, 17 Nov 2009 08:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024467.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024153.do</link>
    <title>Bypassing the blues: How simple collaborative care can help tackle depression after CABG surgery</title>
    <description>
    <![CDATA[ Depression after coronary artery bypass surgery is often overlooked by physicians but is associated with worse outcomes. A new US study illustrates a simple telephone-based approach to tackle this, with nurses encouraging patients to seek help from their primary-care doctors and providing ongoing feedback and review.  ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 18:45:23 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024153.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1024017.do</link>
    <title>Postop anemia in high-CV-risk patients: No CV gains from fixed hemoglobin target in trial</title>
    <description>
    <![CDATA[ A randomized trial found no protection from in-hospital cardiovascular events with a strategy of blood transfusions to maintain hemoglobin above 10 g/dL, compared with a more conservative approach to transfusion therapy, in patients with CV disease or risk factors who underwent hip surgery.   ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 17:45:01 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1024017.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1023939.do</link>
    <title>RECORD AF: Better success with rhythm control, but no difference in outcomes</title>
    <description>
    <![CDATA[ New registry data presented this week showed that cardiologists are more likely to select rhythm control over rate control for the treatment of atrial fibrillation, and this strategy is more likely to lead to successful treatment of AF than the rate-control-based approach. Both strategies are equivalent in terms of their effect on clinical outcomes. ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 17:00:40 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1023939.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1023633.do</link>
    <title>Cangrelor in CHAMPION: What went wrong? </title>
    <description>
    <![CDATA[ Discussion is abounding on why cangrelor did not show benefit over clopidogrel despite the fact that it did inhibit platelet activity more effectively.  ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 15:15:27 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1023633.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1022387.do</link>
    <title>Plasma renin activity associated with cardiovascular events and mortality in HOPE</title>
    <description>
    <![CDATA[ Patients with elevated baseline plasma renin activity levels had a twofold increased risk of total or cardiovascular mortality compared with those with low levels, and the strength of the association persisted after multiple adjustments, including the HOPE score, CRP, and BNP.  ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 14:45:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1022387.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1023209.do</link>
    <title>REPLACE registry finds 15.3% six-month complication rate with pacer and ICD lead replacements</title>
    <description>
    <![CDATA[ The REPLACE registry finds "sobering" comprehensive risk rates with pacemaker and ICD upgrades. ]]>
    </description>
    <pubDate>
    Mon, 16 Nov 2009 09:30:42 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1023209.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1022873.do</link>
    <title>Good news continues for ticagrelor in PLATO STEMI subanalysis </title>
    <description>
    <![CDATA[ Ticagrelor, an investigational antiplatelet agent, may become a new standard of care for the management of patients with STEMI heading for primary PCI, said the lead investigator of the STEMI subset of the PLATO trial. Reporting the new findings here today, he said they were consistent with the overall PLATO results.  ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 19:30:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1022873.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1022265.do</link>
    <title>ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe </title>
    <description>
    <![CDATA[ Extended-release niacin is superior to ezetimibe in its effect on carotid intima-media thickness. While experts say the trial tells clinicians little about ezetimibe, it is a big win for niacin given the substantial regression of atherosclerosis observed at eight and 14 months.  ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 18:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1022265.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1022323.do</link>
    <title>PACE: BiV pacing protects against RV pacing's adverse ventricular effects in randomized trial   </title>
    <description>
    <![CDATA[ In patients with conventional indications for pacing and normal systolic function, preservation of synchrony with biventricular pacing prevented the adverse remodeling effects of right-ventricular-only pacing. But some question the trial's methods.   ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 16:30:23 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1022323.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021875.do</link>
    <title>POPULARity contest: For platelet function assays, what works, what doesn't</title>
    <description>
    <![CDATA[ None of the eight platelet assays studied were able to predict bleeding, but four of the eight, based on ADP-induced platelet aggregation, produced results that correlated with adverse CV outcomes. By contrast, four tests that use shear-stress-induced adhesion-based methods were not predictive. ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 14:15:02 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021875.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021669.do</link>
    <title>PEPCAD-3: Paclitaxel-coated-balloon/stent system misses mark in de novo coronary lesions</title>
    <description>
    <![CDATA[ Inflation of the paclitaxel-delivering balloon followed by a bare-metal stent failed a randomized noninferiority test against the Cypher sirolimus-eluting stent in previously untreated coronary lesions.   ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 10:30:25 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021669.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021541.do</link>
    <title>FRANCE: Transcatheter-valve registry permits "observation" of CoreValve, Sapien differences</title>
    <description>
    <![CDATA[ Results from one of the first registries to evaluate contemporary use of both the Edwards Sapien transcatheter valve and the CoreValve bioprosthesis show that complication rates are low and similar, following a short training period, and that mortality, at least out to six months, is "acceptable" for both types of devices.  ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 09:45:44 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021541.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1020935.do</link>
    <title>Canadian confusion: Primary-care docs lack knowledge of CVD risk factors, prevention</title>
    <description>
    <![CDATA[ Family doctors and general practitioners in Canada are confused about cardiovascular risk assessment in primary prevention, a new survey reveals.   ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 09:00:30 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1020935.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021493.do</link>
    <title>Two-year EXPIRA results suggest mechanical aspiration with primary PCI may reduce mortality</title>
    <description>
    <![CDATA[ Two-year follow-up results from the EXPIRA study show mechanical thrombectomy during primary PCI improves myocardial perfusion and may reduce mortality. ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 09:00:03 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021493.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021445.do</link>
    <title>Experienced operators can switch easily and rapidly to radial-access PCI: RAPTOR</title>
    <description>
    <![CDATA[ Experienced interventional cardiologists can rapidly shift their practice from the femoral-artery to the radial-access approach, with no increase in procedure time and radiation exposure for PCI. Also, the transradial approach leads to a more economic use of hospital resources, say researchers. ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 08:30:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021445.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1021415.do</link>
    <title>CHAMPION: Negative trials but some positive angles for cangrelor?</title>
    <description>
    <![CDATA[ Although neither CHAMPION-PCI nor CHAMPION-PLATFORM showed significant reductions in the primary end point with this new IV antiplatelet agent, some positive effects were seen, suggesting that the drug may yet have a future.  ]]>
    </description>
    <pubDate>
    Sun, 15 Nov 2009 08:00:00 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1021415.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1020447.do</link>
    <title>What's going to be hot at AHA 2009? </title>
    <description>
    <![CDATA[ Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.  ]]>
    </description>
    <pubDate>
    Wed, 11 Nov 2009 09:00:54 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1020447.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1017689.do</link>
    <title>Advocates build support for Canadian Heart Health Strategy in a difficult environment</title>
    <description>
    <![CDATA[ Supporters of the Canadian Heart Health Strategy and Action Plan continue to solicit support from physicians and the public for a comprehensive strategy for improving Canadian's heart health at both the provincial and federal level. ]]>
    </description>
    <pubDate>
    Mon, 02 Nov 2009 11:15:59 EST
    </pubDate>
    <guid>http://www.theheart.org/article/1017689.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1017525.do</link>
    <title>Blood type of pig may be factor in longevity of porcine replacement heart valves</title>
    <description>
    <![CDATA[ Researchers in Ottawa find that the longevity of porcine replacement heart valves may depend partly on whether the blood type of the patient matches the blood type of the valve's "original owner." ]]>
    </description>
    <pubDate>
    Fri, 30 Oct 2009 16:45:00 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1017525.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1017153.do</link>
    <title>Combination drugs for weight loss</title>
    <description>
    <![CDATA[ Two studies presented this week have shown positive effects on weight loss using a combination of agents. ]]>
    </description>
    <pubDate>
    Thu, 29 Oct 2009 15:30:33 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1017153.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1017037.do</link>
    <title>Benefits of targeted lead placement with CRT devices supported by long-term mortality data</title>
    <description>
    <![CDATA[ An additional year of data from the INCREMENTAL study showed that echo-targeted LV lead positioning increased the likelihood of a response to device therapy by about 40% over standard lead placement. But does that difference translate into better long-term outcomes for the patient? ]]>
    </description>
    <pubDate>
    Thu, 29 Oct 2009 15:00:55 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1017037.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016975.do</link>
    <title>First trial of viral-derived protein agent shows promise as anti-inflammatory ACS therapy</title>
    <description>
    <![CDATA[ Inflammatory responses contribute to coronary plaque rupture, thrombosis, and vascular occlusion. Some viruses have proteins that interfere with these inflammatory responses. Researchers have identified a viral-derived protein that may eventually be an anti-inflammatory treatment for coronary syndromes. ]]>
    </description>
    <pubDate>
    Thu, 29 Oct 2009 11:45:16 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016975.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016067.do</link>
    <title>Underutilization of ICDs in CABG patients is worst in women and elderly, Halifax study shows</title>
    <description>
    <![CDATA[ Only 101 of 1169 post-bypass-surgery patients eligible for an ICD got one over a 13-year period in Nova Scotia.  ]]>
    </description>
    <pubDate>
    Wed, 28 Oct 2009 16:45:37 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016067.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016657.do</link>
    <title>Schizophrenia plus diabetes linked with higher CAD yet lower revascularization rates</title>
    <description>
    <![CDATA[ Individuals with schizophrenia and diabetes&#151;as opposed to diabetes only&#151;have a greater risk of CAD but a smaller likelihood of receiving CABG or PCI, a large cohort study suggests. ]]>
    </description>
    <pubDate>
    Wed, 28 Oct 2009 16:30:56 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016657.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016585.do</link>
    <title>Bariatric surgery fails to reduce risk of MI long term</title>
    <description>
    <![CDATA[ After a median follow-up of 12 years, MI rates were essentially the same among those treated with surgery and those who received conventional care for weight loss. ]]>
    </description>
    <pubDate>
    Wed, 28 Oct 2009 14:30:14 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016585.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016353.do</link>
    <title>Lorcaserin passes weight-loss and valvular hurdles in BLOSSOM study</title>
    <description>
    <![CDATA[ Among overweight patients, including those with preexisting echocardiographic valvulopathy, the average weight loss was approximately 5 kg with lorcaserin. Importantly, there were no concerns raised about new or worsening cardiac valve problems with the 5HT2C-receptor agonist. ]]>
    </description>
    <pubDate>
    Tue, 27 Oct 2009 16:15:27 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016353.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1016171.do</link>
    <title>Contrary to common belief, women feel same heart-attack symptoms as men</title>
    <description>
    <![CDATA[ Women and men have the same rates of chest pain and other classic symptoms during ACS, although women are more likely to experience some other symptoms such as jaw and neck pain. ]]>
    </description>
    <pubDate>
    Tue, 27 Oct 2009 14:30:23 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1016171.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1015993.do</link>
    <title>Blood products should be used conservatively in heart-surgery patients, trial shows</title>
    <description>
    <![CDATA[ Administration of blood products to stable patients post-cardiac surgery increases their risk of death, renal failure, and sepsis, according to new research. ]]>
    </description>
    <pubDate>
    Tue, 27 Oct 2009 12:15:25 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1015993.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1015749.do</link>
    <title>ACCORD update: "One size fits all" may not be best glucose-lowering strategy </title>
    <description>
    <![CDATA[ While post hoc analyses of ACCORD data suggest there are subgroups of diabetic patients who may not benefit from an aggressive glucose-lowering approach, similar analyses with ADVANCE data did not identify subgroup differences.    ]]>
    </description>
    <pubDate>
    Tue, 27 Oct 2009 10:00:02 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1015749.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1015787.do</link>
    <title>Experts weigh in on calorie lists on menus, despite "mixed" science</title>
    <description>
    <![CDATA[ Results showing that people eat less when they know how many calories are in that Big Mac are mixed, but experts say that menu labeling provides only upside, with no public-health cost, and that over time results will show the information to have a positive effect on obesity rates in the US. ]]>
    </description>
    <pubDate>
    Mon, 26 Oct 2009 16:45:21 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1015787.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1015367.do</link>
    <title>Less exposure to cardiovascular risk factors with intensive diabetes intervention: Look AHEAD </title>
    <description>
    <![CDATA[ Intensive lifestyle intervention in the management of diabetes produces sustained weight loss and improvements in fitness, as well as improvements in glycemic control, systolic blood pressure, and HDL-cholesterol levels. ]]>
    </description>
    <pubDate>
    Mon, 26 Oct 2009 10:00:00 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1015367.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1014997.do</link>
    <title>Glucose lowering in type 2 diabetes to prevent CVD remains controversial but still important</title>
    <description>
    <![CDATA[ Although the case for intensive glucose lowering in diabetic patients to prevent CVD is not straightforward, glucose control is still important for other reasons, and blood pressure and lipid control should not be neglected, according to debaters at a diabetes meeting.   ]]>
    </description>
    <pubDate>
    Thu, 22 Oct 2009 14:45:51 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1014997.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1014607.do</link>
    <title>Current risk equations may overestimate CVD risk in diabetic patients </title>
    <description>
    <![CDATA[ Researchers using different international databases report that the Framingham and UKPDS risk equations overestimate the probability of CV events in diabetic patients.  ]]>
    </description>
    <pubDate>
    Wed, 21 Oct 2009 10:00:31 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1014607.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1014307.do</link>
    <title>Thiazolidinediones have a role for appropriate diabetic patients</title>
    <description>
    <![CDATA[ After 10 years of clinical use of TZDs, "we are still at the beginning," and randomized controlled trials shed light on their use in appropriate diabetic patients, speakers at a diabetes symposium reported.  ]]>
    </description>
    <pubDate>
    Tue, 20 Oct 2009 12:45:38 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1014307.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1012275.do</link>
    <title>Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim </title>
    <description>
    <![CDATA[ Diabetologists are trying to tease out the best message to convey when it comes to target HbA<sub>1c</sub> levels for primary-care physicians and other nonspecialists who might be treating patients with type 2 diabetes.  ]]>
    </description>
    <pubDate>
    Fri, 09 Oct 2009 16:45:25 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1012275.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1011331.do</link>
    <title>Experts debate bariatric surgery as a cure for diabetes </title>
    <description>
    <![CDATA[ Under the some-say-misguided term "metabolic" surgery, gastric bypass is now being used in some instances to treat diabetics who are not considered morbidly obese. Experts say the mostly circumstantial evidence on this is intriguing, but prospective data are desperately needed in this group of patients. ]]>
    </description>
    <pubDate>
    Thu, 08 Oct 2009 13:15:54 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1011331.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1010567.do</link>
    <title>Hypoglycemia associated with increased risk of MI among US veterans with diabetes </title>
    <description>
    <![CDATA[ Close attention should be paid to diabetes patients who experience an episode of hypoglycemia, because a new case-control study suggests a 65% increased risk of MI in the immediate two-week aftermath of such an event. Doctors should tailor diabetes therapies to minimize the risk of hypoglycemia occurring, say the researchers.  ]]>
    </description>
    <pubDate>
    Mon, 05 Oct 2009 13:45:19 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1010567.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1010255.do</link>
    <title>Insulin glargine and cancer: Association, no causal link </title>
    <description>
    <![CDATA[ That was the conclusion of a recent panel of experts, perhaps alleviating concerns raised by several recent studies.   ]]>
    </description>
    <pubDate>
    Fri, 02 Oct 2009 15:00:18 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1010255.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1009621.do</link>
    <title>Time to act: Cardiologists, diabetes docs, and psychiatrists urged to work together to tackle CVD in the mentally ill </title>
    <description>
    <![CDATA[ Doctors from across the specialties of cardiology, diabetes, and psychiatry are being urged to collaborate to improve care for the mentally ill, who are more likely to die from cardiovascular disease than any other cause. ]]>
    </description>
    <pubDate>
    Wed, 30 Sep 2009 14:00:04 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1009621.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1009297.do</link>
    <title>Kissing-balloon dilatation of side branch not needed with one-stent bifurcation approach</title>
    <description>
    <![CDATA[ With the one-stent technique for the treatment of bifurcation lesions, the use of routine kissing-balloon dilatation of the side branch does not improve six-month clinical outcomes. ]]>
    </description>
    <pubDate>
    Tue, 29 Sep 2009 16:15:30 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1009297.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1009035.do</link>
    <title>BCIS-1 trial: "Bailout" intra-aortic balloon pump beats elective use in low EF/high-risk patients</title>
    <description>
    <![CDATA[ The study provides an important answer to a question that has divided some interventionalists. Those who "swear" by IABP use for all high-risk, low-EF patients should rethink their practice. In hypotensive patients and those with cardiogenic shock, IABPs play a key role.  ]]>
    </description>
    <pubDate>
    Tue, 29 Sep 2009 10:45:47 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1009035.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1008965.do</link>
    <title>FAUST: Ultrasound guidance improves femoral access in cases of high bifurcation, reduces risk of complication</title>
    <description>
    <![CDATA[ <b><i>CORRECTED </i></b><i>// </i>A study has found that although ultrasound imaging doesn't seem to improve upon the overall success rate of fluoroscopy-assisted femoral-access PCI, it does seem to facilitate the procedure, reducing the risk of access complications by 59% and doubling the first-pass success rate. ]]>
    </description>
    <pubDate>
    Tue, 29 Sep 2009 09:45:25 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1008965.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1008623.do</link>
    <title>CHARISMA Genomics Substudy links loss-of-function allele and bleeding</title>
    <description>
    <![CDATA[ Patients who are homozygous for the CYP2C19*2 allele are at increased risk of ischemia but less likely to bleed. Routine genotyping for the variant still isn't recommended. ]]>
    </description>
    <pubDate>
    Mon, 28 Sep 2009 14:15:11 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1008623.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1008155.do</link>
    <title>Reduced bleeding and comparable stent thrombosis with DES and bare-metal stents: HORIZONS-AMI at two years</title>
    <description>
    <![CDATA[ Two-year data showed significant reductions in bleeding and cardiac mortality in patients treated with bivalirudin when compared with those treated with heparin plus a GP IIb/IIIa inhibitor. In the stent arm of the trial, researchers showed that stent thrombosis rates were equivalent between DES and bare-metal stents, although both rates were high, at 4.1%.  ]]>
    </description>
    <pubDate>
    Fri, 25 Sep 2009 17:55:17 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1008155.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1008053.do</link>
    <title>PLATO-Invasive: Impressive ticagrelor results mirror overall trial findings </title>
    <description>
    <![CDATA[ The prespecified subset analysis helps clarify the performance of the drug in patients managed invasively, including adding new insights into its benefits over both the 300-mg and 600-mg loading doses of clopidogrel.  ]]>
    </description>
    <pubDate>
    Fri, 25 Sep 2009 17:30:21 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1008053.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007873.do</link>
    <title>PROSPECT: Vulnerable lesions lead to unstable angina rather than MI or death</title>
    <description>
    <![CDATA[ After successful PCI, 20% of patients go on to have a MACE at three years and 12% of patients develop events from nonculprit lesions. PROSPECT investigators say, however, that events from these nonculprit lesions are more likely to be unstable angina or progressive angina, rather than harder events such as MI or cardiac death. ]]>
    </description>
    <pubDate>
    Fri, 25 Sep 2009 14:15:11 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007873.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007461.do</link>
    <title>BNP-boosting gene variant hints at possible screening, cardioprotective roles  </title>
    <description>
    <![CDATA[ A single-nucleotide polymorphism associated with chronically raised natriuretic-peptide levels is common enough to potentially influence interpretation of BNP and NT-proBNP assays under some circumstances, researchers say; there is increasing evidence that the gene variant may enhance survival in some patient groups. ]]>
    </description>
    <pubDate>
    Fri, 25 Sep 2009 10:45:02 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007461.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007305.do</link>
    <title>COMPARE: "Real-world" randomized trial favors Xience V over Taxus Liberté </title>
    <description>
    <![CDATA[ COMPARE is the second of two large randomized controlled trials comparing a Taxus stent with Xience V to show a clear benefit of the newer stent. ]]>
    </description>
    <pubDate>
    Fri, 25 Sep 2009 08:30:19 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007305.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007269.do</link>
    <title>Doubling dose of clopidogrel benefits STEMI patients without risk of bleeding</title>
    <description>
    <![CDATA[ Doubling the dose of clopidogrel reduced the risk of MI and stent thrombosis in STEMI patients without increasing the risk of bleeding. The benefit extended to patients who received a bare-metal stent or a drug-eluting stent. ]]>
    </description>
    <pubDate>
    Thu, 24 Sep 2009 17:45:49 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007269.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007145.do</link>
    <title>COGENT: No CV events but significant GI benefits of PPI omeprazole</title>
    <description>
    <![CDATA[ The randomized controlled trial results should put a stop to alarmist headlines about PPIs blunting efficacy of antiplatelet drugs, experts say. By withholding PPIs, physicians are doing more harm than good, the results suggest. ]]>
    </description>
    <pubDate>
    Thu, 24 Sep 2009 16:30:07 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007145.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1007049.do</link>
    <title>FAME lives on: FFR results durable at two years</title>
    <description>
    <![CDATA[ The past few cardiology meetings have included data on the FAME study, and TCT 2009 was no exception. Investigators showed that the one-year and 18-month results were durable out to two years, although some researchers would like to see the study replicated to conclusively prove the added value of fractional flow reserve testing. ]]>
    </description>
    <pubDate>
    Thu, 24 Sep 2009 14:45:38 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1007049.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1006629.do</link>
    <title>SIRTAX LATE: No differences in MACE for first-generation stents at five years</title>
    <description>
    <![CDATA[ After one year, Cypher had lower rates of death, MI, or repeat PCIs than Taxus in the SIRTAX trial. But four years later, investigators say all differences between the two have disappeared, in part due to more late "catch-up" with the Cypher.  ]]>
    </description>
    <pubDate>
    Thu, 24 Sep 2009 08:30:17 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1006629.do</guid>
    </item>

    <item>
    <link>http://www.theheart.org/article/1006595.do</link>
    <title>Stent sandwich: First-generation stents equal for Cypher in-stent restenosis</title>
    <description>
    <![CDATA[ Late lumen loss at one year, the primary end point, was equivalent between the Cypher and Taxus stent at one year among patients with restenosis after initial treatment with the Cypher stent.  ]]>
    </description>
    <pubDate>
    Thu, 24 Sep 2009 07:45:13 EDT
    </pubDate>
    <guid>http://www.theheart.org/article/1006595.do</guid>
    </item>

</channel>
</rss>
